Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guides
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks Stock plan guidance
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Schroders Capital GIT joins Neurona Therapeutics funding round
(Sharecast News) - Schroders Capital Global Innovation Trust announced an investment of $1.6m (£1.3m) in Neurona Therapeutics, a prominent US-based clinical-stage cell therapy company, on Friday. The investment by the trust was part of Neurona's series E financing round, which successfully raised $120m.
Schroders said the financing round was co-led by Viking Global Investors and Cormorant Asset Management, and saw participation from a range of investors, both new and existing.
Neurona Therapeutics specialises in the development of allogeneic neural cell therapies aimed at addressing chronic diseases of the nervous system.
The funds procured from the financing round were earmarked to further the advancement of Neurona's pipeline of wholly-owned, off-the-shelf cell therapies across various indications.
Schroders said the lead investigational candidate, NRTX-1001, was currently under evaluation in an ongoing open-label, single-arm phase one and two clinical trial for the treatment of drug-resistant mesial temporal lobe epilepsy (MTLE).
Additionally, there was potential for its application in Alzheimer's disease treatment.
In December, Neurona reported positive outcomes from its clinical trials, indicating that NRTX-1001 had been well-tolerated among initial subjects.
The first two subjects continued to experience a significant reduction of over 95% in overall average monthly seizure counts one year after treatment.
Beyond NRTX-1001, Neurona was actively engaged in the preclinical development of three additional cell therapies.
"We are delighted to make another investment as part of the portfolio sub-strategy of backing innovative life science companies at the near-clinical or clinical stage of development," said lead portfolio manager Tim Creed and co-portfolio manager Harry Raikes in a joint statement.
"We believe Neurona is a highly complementary addition to the company's portfolio.
"This funding will help advance Neurona's cell therapies to address unmet needs in chronic neurological disorders and we are encouraged by the strength of the initial clinical data."
At 1233 GMT, shares in Schroders Capital Global Innovation Trust were down 0.11% in London at 12.34p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
